Navigation Links
GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Date:8/14/2014

SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

The conference is attended by public companies, institutional investors, sophisticated private investors and industry executives.

GenSpera will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss the significance of the recently announced HCC clinical trial update for G-202, its lead drug candidate, as well as provide a corporate overview. The company has released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib ( Nexavar®, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary).  Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study. In addition, imaging analysis demonstrated impressive blockade of tumor blood flow in the single patient evaluated by this method to date.

Hepatocellular carcinoma (HCC) is currently the sixth most common malignancy in the world and the third leading cause of cancer-related mortality worldwide.

Craig Dionne, PhD, GenSpera's CEO said of the pending conference," I am excited to share the recent data and results for G-202 and its efficacy and safety analyses on patients to date. G-202 has potential to treat multiple cancers including prostate cancer and glioblastoma but our primary focus is currently hepatocellular carcinoma (HCC). The liver cancer data we recently presented at APPLE and other sc
'/>"/>

SOURCE GenSpera, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
2. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
3. Aventura Client Presents Enhancing Emergency Department Documentation Efficiency at Optum Client Forum 2014
4. Lpath to Present at 34th Annual Canaccord Genuity Growth Conference
5. Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference
6. Lexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
7. Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
8. Guardant Health to Present at the WedBush 2014 Life Sciences Management Access Conference
9. Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
10. STAAR Surgical To Present At Wedbush And Canaccord Investor Conferences
11. KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Intec Pharma Ltd. (the "Company") (NASDAQ: ... developing drugs based on its proprietary Accordion Pill platform ... offering in the United States ... to the public of $6.00 per ordinary share, before ... are being offered by the Company.  In addition, the ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
(Date:8/4/2015)... -- Second Quarter 2015 Highlights: , ... of 2014 , Net earnings attributable to Team Health ... adjustments , Diluted net earnings per share of $0.39; ... to $99.4 million 2015 Outlook: , ... 24.0% to 26.0%; Adjusted EBITDA margin remains between 10.5% and ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30
... 2011 The grand opening ceremony for the world,s largest ... RNL BIO ( www.rnl.co.kr ), South Korea,s premier ... stem cell medical center in Beijing, China. Beijing RNL Stem ... Research Institute" (President : Li Hailing, www.yandaco.com ). Beijing ...
... harder to crush version of OxyContin® has a lower ... at a conference of law enforcement officers today. Last ... announced that every day 100 people die from drug ... pain relievers. A new formulation of the opioid pain ...
Cached Medicine Technology:RNL Opens the World's Largest Stem Cell Medical Center in Beijing, China 2New OxyContin® Has Lower Street Price Than Old Crushable Formulation 2
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... More than ... Schaumburg renewed their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and ... to each other. Following the ceremony was a reception, with music by the ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking younger – with a ... surgery to achieve this ideal is not. But minimally invasive procedures such as dermal ... cost or lengthy recovery time, according to Valerie Goldburt, MD, PhD , of ...
(Date:8/4/2015)... ... August 04, 2015 , ... In ... filed against Johnson & Johnson report that a new location for pretrial proceedings ... regular news updates and cancer warning information at their website, the Talcum Powder ...
(Date:8/4/2015)... MA (PRWEB) , ... August 04, 2015 , ... Please ... Aneurysm Awareness on Sunday, September 20th at Oneida Shores Park in Brewerton, NY. ... suffering from a ruptured brain aneurysm at the young age of 59. Her family ...
(Date:8/4/2015)... ... 04, 2015 , ... Mr Didier Cauchois, CIO of information ... , Mr Cauchois attributes the success to the dedication from the team ... healthcare technology offered by Winscribe's platform. , "We have already begun to ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... National Heart, Lung, and Blood Institute (NHLBI) and the ... out with recommendations to treat Hypertension.,Control of systolic blood ... pressure. This is a crucial message for health care ... importance of lowering systolic blood pressure to less than ...
... the American Journal of Epidemiology reports that People of ... from most causes except cancer. In a study of ... Jousilahti and his colleagues from the National Public Health ... was an association between adult height and mortality. The ...
... levels of cholesterol but low levels that are making news. ... maybe linked to depression and violent behavior. A new study ... to seven times more likely to report symptoms of severe ... in Durham, N.C. Said, "I think that at ...
... This Symptom. As many as one-third of patients never have ... study published in The Journal of the American Medical Association ... groups likely to have atypical heart attack symptoms, more than ... in more than 400,000 people who were treated for heart ...
... most common cancers in women. If it is caught and ... smear is the standard screening method for the disease. It ... ,Two strains of the human papilloma virus (HPV) are associated ... all women who test positive, develop the disease. ,Swedish researchers ...
... Jewish Medical and Research Center researchers in USA say ... may help prevent asthma later in life. Environmental endotoxin ... homes have high levels of the bacteria by-product. ,"Endotoxin ... that inhibit certain processes in the body that may ...
Cached Medicine News:
... Sprinter balloon incorporates advanced technology, ... crossing ability in the toughest ... will is offered in a ... from the 2.0 4.0 ...
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
Medicine Products: